<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT01817400">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT01817400">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT01817400 on 2013_12_16</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Administrative, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><span class="nolink" title="There is no version prior to this one."><img src="/archive/prev-g.gif" alt="" width="23" height="19" /></span></div><h2>Before</h2><h3><a href="/archive/NCT01817400/2013_03_22">(Updated 2013_03_22)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01817400/2014_01_27/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01817400/2013_12_16">(Updated 2013_12_16)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 18 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  UColorado</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  University of Colorado, Denver</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  12-1414</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U54HD058155</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 18 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  UColorado</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  University of Colorado, Denver</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  12-1414</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U54HD058155</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  NCT01817400</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f21A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none" /><img id="sdiff-collapse-f21A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-f21A-cdiv" class="sdiff-collapsed" title="The middle 397 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none"></div><div id="sdiff-collapse-f21A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity (MARO)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  MARO</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado, Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The study is seeking to understand how being overweight and obese makes women less fertile.  The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and obese.  The present study will try to find the most promising substances by studying small numbers of women and trying to remove the substances that are causing the problem.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis:  A circulating factor or factors, either hormonal, inflammatory or metabolic, causes relative pituitary hypofunction and correction of this reproductive deficit will allow obese women with infertility who have failed to reduce their body weight to normal to conceive, and may also prevent the horizontal passage of an adverse metabolic phenotype to the offspring.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Specific Aim 1: To determine whether aromatase activity is measurable in adipose tissue using the &amp;apos;compound&amp;apos; (see appendix) as a precursor and whether aromatase is decreased in the adipose tissue of obese women, and whether this varies by regional fat location.  The investigators will accomplish this by examining precursor/product ratios of hormones infused through microdialysis using the &amp;apos;compound&amp;apos; as a substrate.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 1: Aromatase activity will be measurable in adipose tissue using testosterone as a precursor.  Estradiol, but not estrone production from androgen precursors will be decreased in obese women relative to those of normal weight.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 2: To determine whether nonspecific, systemic suppression of inflammation will lead to improved reproductive hormonal profiles of luteinizing hormone (LH), follicle stimulating hormone(FSH), Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with low-dose aspirin and polyunsaturated fatty acids (PUFAs).</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 2: A nonspecific, systemic inflammatory suppression therapy will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 3: To determine whether 4 weeks of reduction of circulating insulin will result in improved reproductive hormonal profiles of LH, FSH, Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with pioglitazone. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 3: Chronic lowering of insulin with pioglitazone treatment of obese women will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2017-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 0</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Basic Science</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Pharmacokinetics Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Area under curve (AUC)- urinary pregnandiol glucuronide (Pdg)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estradiol</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 hours</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Luteinizing hormone (LH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estrone conjugates (E1c)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;other_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Follicle stimulating hormone (FSH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/other_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  27</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Infertility, Female</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Obesity</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol.  The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm.  Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants.  Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin.  She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Dietary Supplement</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Vascepa - Fish Oil</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Aspirin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Pioglitazone</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Actos</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled: </div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; intrauterine device (IUD); abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6% </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled:</div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; IUD; abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6%</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Nanette Santoro, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Celeste Robledo</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  303-724-2046</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  celeste.robledo@ucdenver.edu</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  University of Colorado Denver Anschutz Medical Campus</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Aurora</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Colorado</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  80045</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Nanette Santoro, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2013-03-15</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f21B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none" /><img id="sdiff-collapse-f21B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-f21B-cdiv" class="sdiff-collapsed" title="The middle 397 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f21&#39;)" style="display:none"></div><div id="sdiff-collapse-f21B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity (MARO)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  MARO</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado, Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The study is seeking to understand how being overweight and obese makes women less fertile.  The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and obese.  The present study will try to find the most promising substances by studying small numbers of women and trying to remove the substances that are causing the problem.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis:  A circulating factor or factors, either hormonal, inflammatory or metabolic, causes relative pituitary hypofunction and correction of this reproductive deficit will allow obese women with infertility who have failed to reduce their body weight to normal to conceive, and may also prevent the horizontal passage of an adverse metabolic phenotype to the offspring.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Specific Aim 1: To determine whether aromatase activity is measurable in adipose tissue using the &amp;apos;compound&amp;apos; (see appendix) as a precursor and whether aromatase is decreased in the adipose tissue of obese women, and whether this varies by regional fat location.  The investigators will accomplish this by examining precursor/product ratios of hormones infused through microdialysis using the &amp;apos;compound&amp;apos; as a substrate.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 1: Aromatase activity will be measurable in adipose tissue using testosterone as a precursor.  Estradiol, but not estrone production from androgen precursors will be decreased in obese women relative to those of normal weight.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 2: To determine whether nonspecific, systemic suppression of inflammation will lead to improved reproductive hormonal profiles of luteinizing hormone (LH), follicle stimulating hormone(FSH), Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with low-dose aspirin and polyunsaturated fatty acids (PUFAs).</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 2: A nonspecific, systemic inflammatory suppression therapy will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 3: To determine whether 4 weeks of reduction of circulating insulin will result in improved reproductive hormonal profiles of LH, FSH, Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with pioglitazone. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 3: Chronic lowering of insulin with pioglitazone treatment of obese women will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2017-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 0</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Basic Science</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Pharmacokinetics Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Area under curve (AUC)- urinary pregnandiol glucuronide (Pdg)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estradiol</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 hours</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Luteinizing hormone (LH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estrone conjugates (E1c)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;other_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Follicle stimulating hormone (FSH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/other_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  27</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Infertility, Female</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Obesity</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol.  The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm.  Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants.  Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin.  She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Dietary Supplement</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Vascepa - Fish Oil</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Aspirin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Pioglitazone</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Actos</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled: </div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; intrauterine device (IUD); abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6% </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled:</div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; IUD; abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6%</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Nanette Santoro, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Celeste Robledo</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  303-724-2046</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  celeste.robledo@ucdenver.edu</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  University of Colorado Denver Anschutz Medical Campus</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Aurora</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Colorado</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  80045</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Nanette Santoro, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2013-03-15</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2013-03-22</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-12-13</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f421A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none" /><img id="sdiff-collapse-f421A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f421A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none"></div><div id="sdiff-collapse-f421A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f421B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none" /><img id="sdiff-collapse-f421B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f421B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f421&#39;)" style="display:none"></div><div id="sdiff-collapse-f421B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><span class="nolink" title="There is no version prior to this one."><img src="/archive/prev-g.gif" alt="" width="23" height="19" /></span></div><h2>Before</h2><h3><a href="/archive/NCT01817400/2013_03_22">(Updated 2013_03_22)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01817400/2014_01_27/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01817400/2013_12_16">(Updated 2013_12_16)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 18 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  UColorado</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  University of Colorado, Denver</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  12-1414</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U54HD058155</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 18 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  UColorado</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  University of Colorado, Denver</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  12-1414</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U54HD058155</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  NCT01817400</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m21A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none" /><img id="sdiff-collapse-m21A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-m21A-cdiv" class="sdiff-collapsed" title="The middle 352 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none"></div><div id="sdiff-collapse-m21A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity (MARO)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  MARO</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado, Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The study is seeking to understand how being overweight and obese makes women less fertile.  The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and obese.  The present study will try to find the most promising substances by studying small numbers of women and trying to remove the substances that are causing the problem.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis:  A circulating factor or factors, either hormonal, inflammatory or metabolic, causes relative pituitary hypofunction and correction of this reproductive deficit will allow obese women with infertility who have failed to reduce their body weight to normal to conceive, and may also prevent the horizontal passage of an adverse metabolic phenotype to the offspring.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Specific Aim 1: To determine whether aromatase activity is measurable in adipose tissue using the &amp;apos;compound&amp;apos; (see appendix) as a precursor and whether aromatase is decreased in the adipose tissue of obese women, and whether this varies by regional fat location.  The investigators will accomplish this by examining precursor/product ratios of hormones infused through microdialysis using the &amp;apos;compound&amp;apos; as a substrate.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 1: Aromatase activity will be measurable in adipose tissue using testosterone as a precursor.  Estradiol, but not estrone production from androgen precursors will be decreased in obese women relative to those of normal weight.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 2: To determine whether nonspecific, systemic suppression of inflammation will lead to improved reproductive hormonal profiles of luteinizing hormone (LH), follicle stimulating hormone(FSH), Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with low-dose aspirin and polyunsaturated fatty acids (PUFAs).</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 2: A nonspecific, systemic inflammatory suppression therapy will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 3: To determine whether 4 weeks of reduction of circulating insulin will result in improved reproductive hormonal profiles of LH, FSH, Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with pioglitazone. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 3: Chronic lowering of insulin with pioglitazone treatment of obese women will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2017-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 0</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Basic Science</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Pharmacokinetics Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Area under curve (AUC)- urinary pregnandiol glucuronide (Pdg)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estradiol</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 hours</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Luteinizing hormone (LH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estrone conjugates (E1c)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;other_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Follicle stimulating hormone (FSH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/other_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  27</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Infertility, Female</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Obesity</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol.  The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm.  Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants.  Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin.  She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Dietary Supplement</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Vascepa - Fish Oil</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Aspirin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Pioglitazone</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Actos</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled: </div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; intrauterine device (IUD); abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6% </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled:</div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; IUD; abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6%</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Nanette Santoro, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2013-03-15</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m21B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none" /><img id="sdiff-collapse-m21B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-m21B-cdiv" class="sdiff-collapsed" title="The middle 352 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m21&#39;)" style="display:none"></div><div id="sdiff-collapse-m21B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity (MARO)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  MARO</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Mediators of Abnormal Reproductive Function in Obesity</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado, Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The study is seeking to understand how being overweight and obese makes women less fertile.  The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and obese.  The present study will try to find the most promising substances by studying small numbers of women and trying to remove the substances that are causing the problem.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis:  A circulating factor or factors, either hormonal, inflammatory or metabolic, causes relative pituitary hypofunction and correction of this reproductive deficit will allow obese women with infertility who have failed to reduce their body weight to normal to conceive, and may also prevent the horizontal passage of an adverse metabolic phenotype to the offspring.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Specific Aim 1: To determine whether aromatase activity is measurable in adipose tissue using the &amp;apos;compound&amp;apos; (see appendix) as a precursor and whether aromatase is decreased in the adipose tissue of obese women, and whether this varies by regional fat location.  The investigators will accomplish this by examining precursor/product ratios of hormones infused through microdialysis using the &amp;apos;compound&amp;apos; as a substrate.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 1: Aromatase activity will be measurable in adipose tissue using testosterone as a precursor.  Estradiol, but not estrone production from androgen precursors will be decreased in obese women relative to those of normal weight.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 2: To determine whether nonspecific, systemic suppression of inflammation will lead to improved reproductive hormonal profiles of luteinizing hormone (LH), follicle stimulating hormone(FSH), Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with low-dose aspirin and polyunsaturated fatty acids (PUFAs).</div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 2: A nonspecific, systemic inflammatory suppression therapy will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Specific Aim 3: To determine whether 4 weeks of reduction of circulating insulin will result in improved reproductive hormonal profiles of LH, FSH, Estrone conjugates (E1c) and pregnandiol glucuronide (Pdg) in obese women who undergo two menstrual cycles of study: one off treatment and one on treatment.  This aim shall be accomplished by performing daily urinary hormone monitoring of two menstrual cycles, one prior to and one during treatment with pioglitazone. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Hypothesis for specific aim 3: Chronic lowering of insulin with pioglitazone treatment of obese women will result in improved urinary profiles of LH, FSH, E1c and Pdg.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2013-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2017-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 0</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Basic Science</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Pharmacokinetics Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Area under curve (AUC)- urinary pregnandiol glucuronide (Pdg)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estradiol</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 hours</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Luteinizing hormone (LH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Estrone conjugates (E1c)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;other_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Follicle stimulating hormone (FSH)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  two menstrual cycles</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/other_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  27</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Infertility, Female</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Obesity</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol.  The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm.  Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants.  Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin.  She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two &amp;quot;control&amp;quot; probes at each site will be perfused at 2.0 &amp;#181;L/min with Ringer&amp;apos;s solution to measure basal interstitial testosterone and estradiol levels. One &amp;quot;experimental&amp;quot; probe at each site will be perfused with the &amp;apos;compound&amp;apos; 20ug/dl at 2.0 &amp;#181;L/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The &amp;apos;compound&amp;apos; will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second &amp;quot;control&amp;quot; probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Microdialysis</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Dietary Supplement</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Vascepa - Fish Oil</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Aspirin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Anti-inflammatory treatment</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Pioglitazone</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Insulin-lowering therapy</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Actos</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled: </div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; intrauterine device (IUD); abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6% </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  Women aged 18-39* who meet the following criteria will be enrolled:</div>
<div class="sdl4">  </div>
<div class="sdl4">  *Women age 40-60 can be enrolled in Group A </div>
<div class="sdl4">  &amp;#8226;BMI at least 30 kg/m2 (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of chronic disease affecting hormone production, metabolism or clearance</div>
<div class="sdl4">  &amp;#8226;No use of medications known to alter or interact with reproductive hormones or insulin metabolism (e.g. thiazolidinediones, metformin)</div>
<div class="sdl4">  &amp;#8226;No use of reproductive hormones within 3 months of enrollment</div>
<div class="sdl4">  &amp;#8226;No medical conditions that are known to affect urinary hormone excretion or that may interfere with urinary hormone measurement (Groups B and C only)</div>
<div class="sdl4">  &amp;#8226;No history of or active bladder cancer (Group C only, since pioglitazone is contraindicated in individuals with bladder cancer)</div>
<div class="sdl4">  &amp;#8226;Normal prolactin and thyroid stimulating hormone levels at screening</div>
<div class="sdl4">  &amp;#8226;History of regular menstrual cycles every 25-40 days</div>
<div class="sdl4">  &amp;#8226;Use of a reliable method of contraception (female or male partner sterilization; IUD; abstinence; diaphragm)</div>
<div class="sdl4">  &amp;#8226;Hemoglobin A1c &amp;lt;6%</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Nanette Santoro, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  University of Colorado Denver</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2013-03-15</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2013-03-22</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-12-13</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m376A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none" /><img id="sdiff-collapse-m376A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m376A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none"></div><div id="sdiff-collapse-m376A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m376B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none" /><img id="sdiff-collapse-m376B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m376B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m376&#39;)" style="display:none"></div><div id="sdiff-collapse-m376B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f21');
SDiffDeclareUnchCRID('sdiff-collapse-f421');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m21');
SDiffDeclareUnchCRID('sdiff-collapse-m376');
SDiffInit();
</script></body></html>